LANGHORNE, PA — NEXGEL, Inc. (Nasdaq: NXGL) appointed Sequence LifeScience executives Brian Kieser and Kevin Harris to its board following a recent financing tied to NEXGEL’s acquisition of a degenerative disease business from Celularity Inc.
Kieser, chief executive officer of Sequence LifeScience, and Harris, the company’s chief operating officer, join the board after Sequence led financing connected to the transaction, including a previously disclosed $5.5 million strategic investment.
NEXGEL recently completed the acquisition of Celularity’s degenerative disease segment as part of its effort to expand beyond hydrogel-based healthcare and consumer products.
Chief Executive Officer Adam Levy described the appointments as part of a broader strategic relationship between NEXGEL and Sequence LifeScience following the financing round and acquisition closing.
“We could not ask for better strategic partners,” Levy said in a statement.
Kieser also serves as founder and chief executive officer of Fountainhead Biomedical Holdings, a venture platform focused on orthopedic devices, regenerative biologics and biomedical manufacturing.
According to NEXGEL, Kieser holds 14 issued patents related to implanted medical device identification and traceability technologies.
Harris oversees operations at Fountainhead Biomedical Holdings and previously held investment leadership roles at O’Reilly Development Company, Texas Partners Bank and Frost Bank.
NEXGEL manufactures hydrogel products used in healthcare, beauty and over-the-counter consumer applications.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.